An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C

Overview

This study is a two-way, non-interventional long-term dynamic follow-up clinical observational cohort study. In the Second Division of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, chronic hepatitis C patients who were treated with interferon combined with ribavirin (PR) antiviral therapy (PR treatment for 6 months or more) and / or direct acting antivirals (DAAs ), and the baseline, antiviral treatment and discontinuation follow-up data of patients before antiviral treatment were collected, and follow-up observations of patients were carried out for every 3-6 months. The clinical data such as clinical biochemistry, HCV RNA and serological indicators (anti-HCV), AFP, and liver imaging (liver ultrasound) were collected during the study period. The virological response and clinical outcomes of chronic hepatitis C antiviral therapy were observed for at least 144 weeks. The incidence of liver cancer and decompensated liver cirrhosis after discontinuation of the drug was the main evaluation index. The aim is to explore long-term virological response and clinical outcomes, and elucidate its influencing factors.

Full Title of Study: “An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C Patients”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 1, 2020

Detailed Description

This study is a two-way, non-interventional long-term dynamic follow-up clinical observational cohort study. Enrolled in the Second Division of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, via interferon combined with ribavirin (PR) antiviral therapy (PR treatment for 6 months or more) and / or direct acting antivirals (DAAs ) For patients with chronic hepatitis C treated, collect baseline, antiviral treatment and discontinuation follow-up data of patients before antiviral treatment, and follow-up observations of patients enrolled every 3-6 months. Collect clinical data such as clinical biochemistry, HCV RNA and serological indicators (anti-HCV), AFP, and liver imaging (liver ultrasound) during the study period. The virological response and clinical outcomes of chronic hepatitis C antiviral therapy were observed for at least 144 weeks. The incidence of liver cancer and decompensated liver cirrhosis after discontinuation of the drug was the main evaluation index. The aim is to explore long-term virological response and clinical outcomes, and elucidate its influencing factors.

Interventions

  • Drug: interferon combined with ribavirin (PR) antiviral therapy
    • Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
  • Drug: direct antiviral drugs (DAAs)
    • Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)

Arms, Groups and Cohorts

  • interferon combined with ribavirin (PR) antiviral therapy
    • Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
  • direct antiviral drugs (DAAs)
    • Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of liver cancer
    • Time Frame: 144 weeks after withdrawal
    • Incidence of liver cancer after chronic hepatitis C antiviral treatment
  • Incidence of decompensated cirrhosis
    • Time Frame: 144 weeks after withdrawal
    • Incidence of decompensated cirrhosis after chronic hepatitis C antiviral treatment

Secondary Measures

  • Rate of sustained virological response or relapse
    • Time Frame: 144 weeks after withdrawal
    • Rate of sustained virological response or relapse after antiviral treatment of chronic hepatitis C

Participating in This Clinical Trial

Inclusion Criteria

  • Ages 18 to 75; – Unlimited gender; – Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy for 6 months or more) and / or direct antiviral drugs (DAAs). All patients with chronic hepatitis C met the diagnostic criteria of the Chinese Guidelines for the Prevention and Treatment of Chronic Hepatitis C (2015) – No hormones and / or immunosuppressants and other hepatoprotective drugs; – Sign a written informed consent. Exclusion Criteria:

  • Combined with other hepatitis virus (HBV, HDV) infections; – Immune liver disease; – HIV infection; – long-term alcohol and / or other liver damage drugs; – mental illness; – Evidence of liver tumor (liver cancer or AFP> 100 ng / ml); – Decompensated cirrhosis; – Those who have serious heart, brain, lung, kidney and other system diseases that cannot participate in long-term follow-up; – There are hormones and / or immunosuppressants and other hepatoprotective drugs.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Beijing Ditan Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Yao Xie, Director of Hepatology Division 2 – Beijing Ditan Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.